Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics

Hitesh March 29, 2022
thehealthco

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a definitive agreement to divest Sunosi® (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA), to Axsome Therapeutics (Nasdaq: AXSM).

Read More

Next Post

Healthcare Innovations To Watch Out In 2022 & Beyond

Tue Mar 29 , 2022
Innovations in healthtech will keep evolving in the coming years. The rise in disposable income will increase the demand for high-quality healthcare and last-mile accessibility. The digital adoption index has suggested that the healthcare industry in India is embracing technological innovations at a much faster pace now than ever before. […]
thehealthco

You May Like

thehealthco

Click TO Unsubscribe

Email Subscriber

Social Media Icons

Visit Us On TwitterVisit Us On FacebookVisit Us On Linkedin

Click To Data Request

Data Request